Clinical trialEPhase 1Recruiting
GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer
GLP-1 Receptor Agonist Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer
- Outcome
- Ongoing
- Phase
- EPhase 1
- Status
- Recruiting
- Study type
- Interventional
- Start
- 10 October 2026
- Expected end
- 30 June 2028
- Enrollment
- 30 participants
- Sites
- 1
- Primary outcomes
- Incidence of Treatment Emergent Adverse Events [Safety] attributed to GLP1-RA and/or its interaction with chemotherapy
- Sponsor
- Other
- Results posted
- No
- Last update
- 18 September 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try